ALN [American Lorain] S-1: (Original Filing)

[____________________________ FORM S-1 UNDER THE SECURITIES ACT OF 1933 AMERICAN LORAIN CORPORATION Nevada 2068 87-0430320 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification No.) Beihuan Road United Corporate Services, Inc. (877) 734-8300 Copies to: Peter G. Smith, Esq. Bill Huo, Esq. Ari Edelman, Esq. Kramer Levin Naftalis & Frankel LLP 1177] [To: Board of Directors and Shareholders Consent of Independent Registered Public Accounting Firm We hereby consent to your disclosure of our audit report dated February 18, 2009 on the consolidated financial statements as of and for the years ended December 31, 2008 and 2007, of American Lorain Corporation, in the Registration Statement on Form S-1. For the purpose of the]

ALN [American Lorain] S-1: ____________________________ FORM S-1 UNDER THE SECURITIES ACT OF

[____________________________ FORM S-1 UNDER THE SECURITIES ACT OF 1933 AMERICAN LORAIN CORPORATION Nevada 2068 87-0430320 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification No.) Beihuan Road United Corporate Services, Inc. (877) 734-8300 Copies to: Peter G. Smith, Esq. Bill Huo, Esq. Ari Edelman, Esq. Kramer Levin Naftalis & Frankel LLP 1177] [To: Board of Directors and Shareholders Consent of Independent Registered Public Accounting Firm We hereby consent to your disclosure of our audit report dated February 18, 2009 on the consolidated financial statements as of and for the years ended December 31, 2008 and 2007, of American Lorain Corporation, in the Registration Statement on Form S-1. For the purpose of the]

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities -Sinovac to Own 55% in Joint Venture by Year End 2010- BEIJING, Nov. 25 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today that it executed a joint venture (JV) agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian).] [01 - 32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]

By | 2016-03-24T03:55:56+00:00 November 27th, 2009|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Establishes Joint Venture to Expand Human-Use Vaccine

[Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities -Sinovac to Own 55% in Joint Venture by Year End 2010- BEIJING, Nov. 25 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today that it executed a joint venture (JV) agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian).] [01 - 32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]

By | 2016-03-24T03:57:28+00:00 November 27th, 2009|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

EFUT [eFuture] 6-K: (Original Filing)

[eFuture Announces Second Quarter 2009 Unaudited Financial Results and First Quarter 2009 Unaudited Restated Financial Results BEIJING, PRC As noted in previous press releases, the Company reviewed its accounting for certain matters in the First Quarter and has determined that a restatement of unaudited financial information for the First Quarter is appropriate. The Company previously released unaudited financial information for] [FORM 6-K eFuture Information Technology Inc. 8/F TopNew Tower 2 15 Guanghua Road Chaoyang District Beijing 100026, People’s Republic of China 86-10-51650988 x o Form 20-F o x 2 EFUTURE INFORMATION TECHNOLOGY INC.]

By | 2016-04-01T06:09:43+00:00 November 27th, 2009|Categories: Chinese Stocks, EFUT, SEC Original|Tags: , , , , , |0 Comments

JFC [JPMORGAN CHINA REGION FUND,] N-Q: JF China Region Fund, INVESTMENT PORTFOLIO DESCRIPTIONS MARKETMMON

[JF China Region Fund, INVESTMENT PORTFOLIO DESCRIPTIONS MARKETMMON STOCKS (unless otherwise noted) CHINA (37.0%)mmercial Banks (12.8%) Bank of China H 5,465,000 2,877,039 Bank ofmmunications H 836,000 1,018,295 Chinanstruction Bankrp., H 5,342,000 4,266,680 Industrial &mmercial Bank of China, H 4,912,000 3,701,406] [OF THERBANES-OXLEY ACT I, Simon Crinage, certify that: 1. I have reviewed this report on Form N-Q of JF China Region Fund,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the]

By | 2016-01-13T09:41:22+00:00 November 27th, 2009|Categories: Chinese Stocks, JFC, Webplus ver|Tags: , , , |0 Comments

EFUT [eFuture] 6-K: eFuture Announces Second Quarter 2009 Unaudited Financial Results

[eFuture Announces Second Quarter 2009 Unaudited Financial Results and First Quarter 2009 Unaudited Restated Financial Results BEIJING, PRC As noted in previous press releases, the Company reviewed its accounting for certain matters in the First Quarter and has determined that a restatement of unaudited financial information for the First Quarter is appropriate. The Company previously released unaudited financial information for] [FORM 6-K eFuture Information Technology Inc. 8/F TopNew Tower 2 15 Guanghua Road Chaoyang District Beijing 100026, People’s Republic of China 86-10-51650988 x o Form 20-F o x 2 EFUTURE INFORMATION TECHNOLOGY INC.]

By | 2016-04-01T06:10:37+00:00 November 27th, 2009|Categories: Chinese Stocks, EFUT, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar